# Dose-ranging Study

> **NCT01712451** · PHASE2 · COMPLETED · sponsor: **Neothetics, Inc** · enrollment: 200 (actual)

## Conditions studied

- Abdominal Contour Defects

## Interventions

- **DRUG:** salmeterol xinafoate, fluticasone propionate
- **DRUG:** Placebo
- **DRUG:** salmeterol xinafoate

## Key facts

- **NCT ID:** NCT01712451
- **Lead sponsor:** Neothetics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2015-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01712451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01712451, "Dose-ranging Study". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT01712451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*